Pharmaceuticals & Biotech South Korean Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech South Korean Investing Ideas
Binex pivot to a global bio-CDMO requires more than Biosecure Act tailwinds; it demands a total cultural evolution from its 2021 compliance
Binex wants to shift from a generic drug maker into a global partner for complex biologic medicines, but a repeat history of rule-breaking raises a bigger question: can the company truly change how it operates. The stock looks cheap for reasons that go beyond industry tailwinds, and the next few years hinge on whether management can rebuild trust with regulators and large drugmakers.Read more
AN
₩22.57k
67.7% undervalued intrinsic discount
Fair Value
Profit Margin
14.63%
Future PE
21x
Price in 2031
₩31.71k
